The price of Definitive Healthcare Corp (NASDAQ: DH) closed at $8.01 in the last session, down -0.12% from day before closing price of $8.02. In other words, the price has decreased by -$0.01 from its previous closing price. On the day, 576597 shares were traded.
Ratios:
We take a closer look at DH’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 3.06 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 24.68. For the most recent quarter (mrq), Quick Ratio is recorded 2.23 and its Current Ratio is at 2.23. In the meantime, Its Debt-to-Equity ratio is 0.31 whereas as Long-Term Debt/Eq ratio is at 0.29.
Robert W. Baird Downgraded its Outperform to Neutral on July 24, 2023, while the target price for the stock was maintained at $13.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 24 ’23 when SEA VII Management, LLC sold 6,656 shares for $9.39 per share. The transaction valued at 62,500 led to the insider holds 1,441,657 shares of the business.
SEA VII Management, LLC sold 6,240 shares of DH for $56,846 on May 12 ’23. The Director now owns 1,743,478 shares after completing the transaction at $9.11 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DH now has a Market Capitalization of 944.14M and an Enterprise Value of 904.00M. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.75 while its Price-to-Book (P/B) ratio in mrq is 1.08. Its current Enterprise Value per Revenue stands at 3.60 whereas that against EBITDA is -3.75.
Stock Price History:
Over the past 52 weeks, DH has reached a high of $12.45, while it has fallen to a 52-week low of $5.53. The 50-Day Moving Average of the stock is 8.70, while the 200-Day Moving Average is calculated to be 8.97.
Shares Statistics:
According to the various share statistics, DH traded on average about 576.28K shares per day over the past 3-months and 449.13k shares per day over the past 10 days. A total of 116.56M shares are outstanding, with a floating share count of 47.77M. Insiders hold about 59.42% of the company’s shares, while institutions hold 44.71% stake in the company. Shares short for DH as of Mar 15, 2024 were 4.83M with a Short Ratio of 8.38, compared to 4.89M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 4.10% and a Short% of Float of 8.88%.
Earnings Estimates
The company has 12 analysts who recommend its stock at the moment. On average, analysts expect EPS of $0.08 for the current quarter, with a high estimate of $0.09 and a low estimate of $0.08, while EPS last year was $0.06. The consensus estimate for the next quarter is $0.09, with high estimates of $0.1 and low estimates of $0.08.
Analysts are recommending an EPS of between $0.38 and $0.34 for the fiscal current year, implying an average EPS of $0.38. EPS for the following year is $0.42, with 11 analysts recommending between $0.46 and $0.39.
Revenue Estimates
According to 12 analysts, the current quarter’s revenue is expected to be $63.99M. It ranges from a high estimate of $64.68M to a low estimate of $63.6M. As of the current estimate, Definitive Healthcare Corp’s year-ago sales were $59.2M, an estimated increase of 8.10% from the year-ago figure. For the next quarter, 12 analysts are estimating revenue of $65.19M, an increase of 6.90% less than the figure of $8.10% in the same quarter last year. There is a high estimate of $66.56M for the next quarter, whereas the lowest estimate is $63M.
A total of 13 analysts have provided revenue estimates for DH’s current fiscal year. The highest revenue estimate was $268.26M, while the lowest revenue estimate was $264M, resulting in an average revenue estimate of $266.27M. In the same quarter a year ago, actual revenue was $251.41M, up 5.90% from the average estimate. Based on 12 analysts’ estimates, the company’s revenue will be $286.8M in the next fiscal year. The high estimate is $292.81M and the low estimate is $278.9M. The average revenue growth estimate for next year is up 7.70% from the average revenue estimate for this year.
